Enveda Biosciences Raises $55M in Funding
Summary
Enveda Biosciences, a Boulder, CO-based biotechnology company using AI to translate nature into new medicines, raised a new financing round of $55m to add to its $119m combined Series B and B1. The closing of this Series B2 round brings the total capital that Enveda has raised to $230m. Led by Viswa Colluru, Ph.D., CEO and Founder, Enveda is a drug discovery and development company using the latest AI-powered technologies to translate nature into new medicines. The company’s proprietary platform solves obstacles in natural product drug discovery including active molecule identification, property and structure prioritization, amenability to medicinal chemistry, and large-scale material access. The lead program for atopic dermatitis is a novel oral first-in-class anti-inflammatory agent that has demonstrated remarkable efficacy and high safety margins in preclinical studies.